Endo International’s (ENDP) “Hold” Rating Reaffirmed at Oppenheimer
Oppenheimer reaffirmed their hold rating on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a research report sent to investors on Tuesday morning. Oppenheimer also issued estimates for Endo International’s Q1 2018 earnings at $0.54 EPS, Q2 2018 earnings at $0.59 EPS, Q3 2018 earnings at $0.61 EPS, Q4 2018 earnings at $0.64 EPS, FY2018 earnings at $2.38 EPS, FY2019 earnings at $2.48 EPS, FY2020 earnings at $2.63 EPS, FY2021 earnings at $2.75 EPS and FY2022 earnings at $2.91 EPS.
Several other research analysts have also recently issued reports on ENDP. Canaccord Genuity set a $7.00 target price on Endo International and gave the stock a hold rating in a research report on Tuesday. Cantor Fitzgerald set a $7.00 target price on Endo International and gave the stock a hold rating in a research report on Tuesday. Barclays dropped their target price on Endo International from $15.00 to $10.00 and set an equal weight rating on the stock in a research report on Friday, February 23rd. ValuEngine cut Endo International from a buy rating to a hold rating in a research report on Friday, February 2nd. Finally, JMP Securities cut Endo International from an outperform rating to a market perform rating in a research report on Monday, February 26th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Endo International currently has a consensus rating of Hold and a consensus price target of $10.32.
Endo International (NASDAQ ENDP) opened at $6.87 on Tuesday. The stock has a market capitalization of $1,460.00, a PE ratio of -1.24, a price-to-earnings-growth ratio of 2.59 and a beta of 0.35. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.02 and a quick ratio of 0.86. Endo International has a 12-month low of $5.77 and a 12-month high of $14.15.
A number of institutional investors and hedge funds have recently modified their holdings of ENDP. Paloma Partners Management Co bought a new stake in Endo International during the 4th quarter valued at approximately $122,000. Oakbrook Investments LLC bought a new stake in Endo International during the 4th quarter valued at approximately $133,000. LMR Partners LLP bought a new stake in Endo International during the 3rd quarter valued at approximately $148,000. Xact Kapitalforvaltning AB bought a new stake in Endo International during the 4th quarter valued at approximately $157,000. Finally, Elkfork Partners LLC bought a new stake in Endo International during the 4th quarter valued at approximately $194,000. 92.54% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dailypolitical.com/2018/03/03/endo-internationals-endp-hold-rating-reaffirmed-at-oppenheimer.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.